SCHEMBL26014

SCHEMBL26014

C/C=C/CCC(N)=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3982965 1.00
SCHEMBL13626153 0.86
SCHEMBL1270703 0.86
SCHEMBL1270704 0.86
SCHEMBL3901539 0.84 FAAH (0.65)
SCHEMBL3901535 0.84 FAAH (0.65)
SCHEMBL17352280 0.82 FAAH (0.69)
SCHEMBL8696497 0.82 FAAH (0.69)
SCHEMBL8696500 0.82 FAAH (0.69)
SCHEMBL17352281 0.82 FAAH (0.69)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1021 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2018102261-A2 BORONIC DERIVATIVES HYDROXAMATES AS ANTICANCER AGENTS XAVIER UNIVERSITY OF LOUISIANA (US) 2018-06-07 WO claimed
US-20120063996-A1 NOVEL NIMESULIDE COMPOSITIONS ELAN PHARMA INTERNATIONAL LTD. 2012-03-15 US claimed
EP-1617816-B1 NANOPARTICULATE MELOXICAN FORMULATIONS ELAN PHARMA INT LTD (IE) 2009-05-13 EP claimed
EP-1981502-A2 PHARMACEUTICAL COMPOSITION CONTAINING A CENTRAL OPIOID AGONIST, A CENTRAL OPIOID ANTAGONIST, AND A PERIPHERAL OPIOID ANTAGONIST, AND METHOD FOR MAKING THE SAME Harrogate Holdings (BM) 2008-10-22 EP claimed
EP-1938803-A2 Formulations comprising nanoparticulate meloxican Elan Pharma International Limited (IE) 2008-07-02 EP claimed
CN-100346832-C Pharmaceutical dosage form for transmucosal delivery PHARMACIA CORP (US) 2007-11-07 CN claimed
WO-2007088489-A2 PHARMACEUTICAL COMPOSITION CONTAINING A CENTRAL OPIOID AGONIST, A CENTRAL OPIOID ANTAGONIST, AND A PERIPHERAL OPIOID ANTAGONIST, AND METHOD FOR MAKING THE SAME HARROGATE HOLDINGS (US) 2007-08-09 WO claimed
US-20070185145-A1 Pharmaceutical composition containing a central opioid agonist, a central opioid antagonist, and a peripheral opioid antagonist, and method for making the same HARROGATE HOLDINGS (BM) 2007-08-09 US claimed
EP-1480624-B1 PHARMACEUTICAL TABLET PHARMACIA CORP (US) 2006-11-29 EP claimed
EP-1471890-B1 PHARMACEUTICAL DOSAGE FORM FOR MUCOSAL DELIVERY PHARMACIA CORP (US) 2006-09-27 EP claimed
WO-2004082719-A1 DISPERSIBLE PHARMACEUTICAL COMPOSITION FOR TREATMENT OF MASTITIS AND OTIC DISORDERS PHARMACIA CORPORATION (US) 2004-09-30 WO claimed
US-20040156872-A1 Novel nimesulide compositions ELAN PHARMA INTERNATIONAL LTD. 2004-08-12 US claimed
US-20030235617-A1 Pharmaceutical dosage form for mucosal delivery MCNEIL-PPC, INC 2003-12-25 US claimed
US-20030180357-A1 Pharmaceutical tablet MCNEIL-PPC, INC 2003-09-25 US claimed
EP-1336602-A1 Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases Scaramuzzino, Giovanni (IT) 2003-08-20 EP claimed
WO-2003066029-A2 PHARMACEUTICAL DOSAGE FORM FOR MUCOSAL DELIVERY PHARMACIA CORPORATION (US) 2003-08-14 WO claimed
WO-2003066030-A2 PHARMACEUTICAL TABLET PHARMACIA CORPORATION (US) 2003-08-14 WO claimed
CN-1294519-A Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient INPHARMA SA (CH) 2001-05-09 CN claimed
EP-1073470-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2001-02-07 EP claimed
WO-2000048636-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2000-08-24 WO claimed